Muhammad Bilal Butt
Abstract
The localization and therapeutic efficiencies of radiolabeled compounds showed limited consequence for various infections including cancerous cells. The localization of cancer cells in living system by biomolecules incorporated with β-emitter radioisotope 177Lu (Emax=0.497Mev) owning the half-life of 6.639 days proved as an efficient agent for radioimmunotherapy, bone pain palliation and targeted radiotherapy. 177Lu is found to be an effective therapeutic radionuclide due to its distinctive nuclear decay properties. Preparation of 177Lu-labeled biomolecules with high percentage radiolabeling yield may only be possible by carefully optimizing different reaction parameters including amount of ligand, pH, buffer used, incubation period, reducing agent and reaction period. In this review, specific parameters for the preparation of 177Lu-labeled antibodies, peptides and miscellaneous compounds along with selective therapeutic applications are described.